---
title: "Stifel Nicolaus Sticks to Their Buy Rating for Inhibrx Biosciences Inc (INBX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286568281.md"
description: "Stifel Nicolaus has maintained a Buy rating for Inhibrx Biosciences Inc (INBX) with a price target of $325.00. Analyst Dara Azar, noted for a 27.3% average return, follows a similar Buy rating from LifeSci Capital, which set a price target of $230.00."
datetime: "2026-05-15T12:45:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286568281.md)
  - [en](https://longbridge.com/en/news/286568281.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286568281.md)
generator: "portal-rs"
---

# Stifel Nicolaus Sticks to Their Buy Rating for Inhibrx Biosciences Inc (INBX)

In a report released today, Dara Azar from Stifel Nicolaus reiterated a Buy rating on Inhibrx Biosciences Inc, with a price target of $325.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Azar is a 2-star analyst with an average return of 27.3% and a 66.67% success rate.

In a report released on May 11, LifeSci Capital also maintained a Buy rating on the stock with a $230.00 price target.

### Related Stocks

- [INBX.US](https://longbridge.com/en/quote/INBX.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)

## Related News & Research

- [Should FDA Review of Ozekibart and INBRX-106 Data Milestones Require Action From Inhibrx (INBX) Investors?](https://longbridge.com/en/news/296008452.md)
- [Inhibrx Biosciences Q2 net loss widens on higher expenses](https://longbridge.com/en/news/295839677.md)
- [Inhibrx Biosciences (INBX) to Announce Quarterly Earnings on Wednesday](https://longbridge.com/en/news/294964621.md)
- [Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer | INBX Stock News](https://longbridge.com/en/news/283402185.md)
- [Inhibrx Biosciences's BLA Filing For Ozekibart Gets FDA Acceptance](https://longbridge.com/en/news/289792872.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**